Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.

Original title: “LifeMine raises $263M in mission to improve organ transplant aftercare”

For example, in October 2023, the ... to advancing novel treatments for rare diseases. This transatlantic, hybrid non-profit/for-profit initiative aims to identify, fund, and fast-track up to 40 groundbreaking therapies into clinical trials over the next decad... For example, in October 2023, the Oxford-Harrington Rare Disease Centre in the UK launched the Therapeutics Accelerator, a pioneering project dedicated to advancing novel treatments for rare diseases. This transatlantic, hybrid non-profit/for-profit initiative aims to identify, fund, and fast-track up to 40 groundbreaking therapies into clinical trials over the next decade. The rare diseases treatment market is set to undergo remarkable expansion over the coming years driven by advancements in medical science and increasing global awareness With a growing emphasis on personalized medicine and innovative therapies this sector is drawing significant ... Press release - The Business Research Company - Overview of the Rare Diseases Treatment Market: Key Trends, Market Structure, and Top Player Analysis - published on openPR.com Comprehensive Breakdown of Market Segments in Rare Diseases Treatment The report divides the rare diseases treatment market into several critical segments to provide a detailed understanding: 1) Drug Type: - Originator Drugs (Patented Molecules) - Generic Drugs 2) Drug Class: - Biologics - Organic Compounds 3) Mode of Administration: - Injectable - Oral - Other Modes of Administration 4) Therapeutic Areas: - Cancer - Neurological Conditions - Cardiovascular Conditions - Musculoskeletal Conditions - Hematologic Disorders - Infectious Diseases - Metabolic Disorders - Endocrine Disorders - Other

Original title: “Overview of the Rare Diseases Treatment Market: Key Trends, Market Structure, and Top Player Analysis”

While biotechs and contract research organizations each have their advantages, that doesn’t mean both options work for everyone. Two experts discuss the differing environments and how to pick between them.

Original title: “CROs vs. biotechs: Finding the right fit”

A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Original title: “Lilly, FDA retatrutide biologic dispute comes to a head as submission nears”

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

Original title: “Lilly climbs, Novo falls as obesity drug battle intensifies”

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Original title: “Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch”

HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.

Original title: “Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts”

Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.

Original title: “Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A”